Antidepressants in long-term therapy: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors

R. M A Hirschfeld, R. Judge

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective: Although depression has been shown to be a long-term disorder, most research studies have concentrated on its acute treatment. Method: A literature review of the use of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) in long-term treatment of depression was performed and recommendations regarding long-term treatment were summarized. Results: Studies conclusively document the need for continuation treatment after initial remission of symptoms to prevent relapse. Studies also suggest that continuation treatment should last a minimum of 3-6 months following acute response. Conclusions from a few maintenance studies clearly show that recurrence rates are lower when patients at risk for recurrence continue their active treatment at its original dose than when they are switched to placebo. Conclusion: Overall, studies conclude that depression is a recurrent, often chronic, lifetime illness requiring long-term treatment. Continuation therapy of 3 to 6 months after acute stabilization should be considered standard for all depressed patients, and maintenance therapy should be considered for many depressed patients. Newer agents, such as the SSRIs, are preferable to the TCAs for long-term treatment based on their superior tolerability and safety. However, because of the limited number of maintenance studies, further studies using a prospective, randomized design are needed to address this issue.

Original languageEnglish (US)
Pages (from-to)35-38
Number of pages4
JournalActa Psychiatrica Scandinavica, Supplement
Volume101
Issue number403
StatePublished - 2000

Fingerprint

Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Antidepressive Agents
Therapeutics
Recurrence
Maintenance
Chronic Disease
Placebos
Safety

Keywords

  • Long-term
  • SSRI
  • TCA

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Antidepressants in long-term therapy : A review of tricyclic antidepressants and selective serotonin reuptake inhibitors. / Hirschfeld, R. M A; Judge, R.

In: Acta Psychiatrica Scandinavica, Supplement, Vol. 101, No. 403, 2000, p. 35-38.

Research output: Contribution to journalArticle

@article{222d118794f24b2bb83d78ccd2f24808,
title = "Antidepressants in long-term therapy: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors",
abstract = "Objective: Although depression has been shown to be a long-term disorder, most research studies have concentrated on its acute treatment. Method: A literature review of the use of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) in long-term treatment of depression was performed and recommendations regarding long-term treatment were summarized. Results: Studies conclusively document the need for continuation treatment after initial remission of symptoms to prevent relapse. Studies also suggest that continuation treatment should last a minimum of 3-6 months following acute response. Conclusions from a few maintenance studies clearly show that recurrence rates are lower when patients at risk for recurrence continue their active treatment at its original dose than when they are switched to placebo. Conclusion: Overall, studies conclude that depression is a recurrent, often chronic, lifetime illness requiring long-term treatment. Continuation therapy of 3 to 6 months after acute stabilization should be considered standard for all depressed patients, and maintenance therapy should be considered for many depressed patients. Newer agents, such as the SSRIs, are preferable to the TCAs for long-term treatment based on their superior tolerability and safety. However, because of the limited number of maintenance studies, further studies using a prospective, randomized design are needed to address this issue.",
keywords = "Long-term, SSRI, TCA",
author = "Hirschfeld, {R. M A} and R. Judge",
year = "2000",
language = "English (US)",
volume = "101",
pages = "35--38",
journal = "Acta Psychiatrica Scandinavica, Supplement",
issn = "0065-1591",
publisher = "Wiley-Blackwell",
number = "403",

}

TY - JOUR

T1 - Antidepressants in long-term therapy

T2 - A review of tricyclic antidepressants and selective serotonin reuptake inhibitors

AU - Hirschfeld, R. M A

AU - Judge, R.

PY - 2000

Y1 - 2000

N2 - Objective: Although depression has been shown to be a long-term disorder, most research studies have concentrated on its acute treatment. Method: A literature review of the use of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) in long-term treatment of depression was performed and recommendations regarding long-term treatment were summarized. Results: Studies conclusively document the need for continuation treatment after initial remission of symptoms to prevent relapse. Studies also suggest that continuation treatment should last a minimum of 3-6 months following acute response. Conclusions from a few maintenance studies clearly show that recurrence rates are lower when patients at risk for recurrence continue their active treatment at its original dose than when they are switched to placebo. Conclusion: Overall, studies conclude that depression is a recurrent, often chronic, lifetime illness requiring long-term treatment. Continuation therapy of 3 to 6 months after acute stabilization should be considered standard for all depressed patients, and maintenance therapy should be considered for many depressed patients. Newer agents, such as the SSRIs, are preferable to the TCAs for long-term treatment based on their superior tolerability and safety. However, because of the limited number of maintenance studies, further studies using a prospective, randomized design are needed to address this issue.

AB - Objective: Although depression has been shown to be a long-term disorder, most research studies have concentrated on its acute treatment. Method: A literature review of the use of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) in long-term treatment of depression was performed and recommendations regarding long-term treatment were summarized. Results: Studies conclusively document the need for continuation treatment after initial remission of symptoms to prevent relapse. Studies also suggest that continuation treatment should last a minimum of 3-6 months following acute response. Conclusions from a few maintenance studies clearly show that recurrence rates are lower when patients at risk for recurrence continue their active treatment at its original dose than when they are switched to placebo. Conclusion: Overall, studies conclude that depression is a recurrent, often chronic, lifetime illness requiring long-term treatment. Continuation therapy of 3 to 6 months after acute stabilization should be considered standard for all depressed patients, and maintenance therapy should be considered for many depressed patients. Newer agents, such as the SSRIs, are preferable to the TCAs for long-term treatment based on their superior tolerability and safety. However, because of the limited number of maintenance studies, further studies using a prospective, randomized design are needed to address this issue.

KW - Long-term

KW - SSRI

KW - TCA

UR - http://www.scopus.com/inward/record.url?scp=0034565204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034565204&partnerID=8YFLogxK

M3 - Article

C2 - 11019933

AN - SCOPUS:0034565204

VL - 101

SP - 35

EP - 38

JO - Acta Psychiatrica Scandinavica, Supplement

JF - Acta Psychiatrica Scandinavica, Supplement

SN - 0065-1591

IS - 403

ER -